BIO-CHEM(SH:603360)2022-08-15 16:00Financial Performance - The company's operating revenue for the first half of 2022 reached RMB 660,442,971.57, representing a 38.98% increase compared to RMB 475,192,916.05 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was RMB 227,587,040.03, an increase of 84.86% from RMB 123,116,314.54 in the previous year[19]. - The net cash flow from operating activities was RMB 190,763,774.39, showing a significant increase of 105.77% compared to RMB 92,706,684.08 in the same period last year[19]. - Basic earnings per share for the first half of 2022 were RMB 0.91, a 93.62% increase compared to RMB 0.47 in the same period last year[20]. - The weighted average return on equity rose to 19.56%, an increase of 7.4 percentage points from 12.16% in the previous year[21]. - The company reported a net profit excluding non-recurring gains and losses of RMB 226,278,023.88, which is an 88.20% increase from RMB 120,234,945.50 in the same period last year[19]. - The diluted earnings per share also stood at RMB 0.91, marking a 93.62% increase compared to RMB 0.47 in the previous year[21]. - Operating profit for the first half of 2022 was ¥267,659,861.76, compared to ¥144,863,414.65 in the first half of 2021, reflecting an increase of 84.8%[98]. - Net profit for the first half of 2022 was ¥227,587,040.03, up 84.9% from ¥123,116,314.54 in the first half of 2021[98]. - Total comprehensive income for the first half of 2022 was ¥246,363,622.26, compared to ¥133,565,634.28 in the first half of 2021, reflecting strong growth[101]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 1,625,211,546.80, a decrease of 2.72% from RMB 1,670,722,296.11 at the end of the previous year[19]. - Total liabilities decreased from ¥621,067,170.25 to ¥343,350,084.56, a decline of approximately 44.7%[91]. - The company's total assets decreased from ¥1,670,722,296.11 to ¥1,625,211,546.80, a reduction of about 2.7%[91]. - The company's retained earnings increased from ¥656,429,160.01 to ¥884,016,200.04, reflecting a growth of approximately 34.6%[91]. - The total equity increased to ¥1,384,170,913.10 from ¥1,133,201,098.34, indicating a growth of 22.1%[95]. Production Capacity and Market Position - The company has over 40,000 tons/year of production capacity for isothiazolinone industrial biocides, making it the largest producer in Asia[24]. - Sales revenue from isothiazolinone industrial biocides accounted for 99.72% of the company's total revenue, providing stable cash flow[28]. - The company has established stable long-term partnerships with major clients such as Lanxess and Oshaida, enhancing its market position[24]. - The company has a flexible production model that allows for capacity adjustments based on sales plans, ensuring timely product supply[28]. Research and Development - Research and development expenses increased by 116.12% to 31.14 million RMB, reflecting the company's commitment to innovation[34]. - The company has been recognized as a high-tech enterprise since October 2011, holding multiple invention patents and a strong R&D team[29]. - The company plans to continue its focus on research and development in new chemical products to enhance market competitiveness[123]. Environmental Compliance and Safety - The company maintains a high standard of safety and environmental protection, complying with national and local environmental quality standards[29]. - The company reported a chemical oxygen demand (COD) discharge of 40.48 tons, which is compliant with environmental standards[58]. - The company’s nitrogen oxides emissions were recorded at 5.156 tons, also meeting the required standards[58]. - The company has completed the revision of the emergency response plan for environmental incidents in May 2022, which has been filed with the local environmental bureau[63]. - The company has established a hazardous waste disposal process that complies with relevant laws and regulations[62]. Shareholder and Stock Information - The company reported a total share count of 258,952,000 after a reduction of 2,394,400 shares, representing a decrease of approximately 0.92%[72]. - The top shareholder, Dalian Tongyun Investment Co., Ltd., held 77,106,968 shares, accounting for 29.78% of total shares, with 38,800,000 shares pledged[79]. - The company repurchased and canceled a total of 2,394,400 restricted shares due to performance assessment not meeting targets and the departure of 4 incentive plan participants, reducing total shares from 26,134,640 to 25,895,200[74]. - The company has implemented a stock incentive plan, although there have been no recent developments[54]. Financial Strategy and Cash Flow - The company incurred financial expenses of -¥9,966,883.98, a significant improvement compared to ¥554,300.05 in the previous year[100]. - The company received CNY 50,000,000.00 in borrowings during the first half of 2022, a significant decrease from CNY 398,485,572.00 in the same period of 2021, indicating a shift in financing strategy[107]. - The total cash inflow from financing activities was CNY 127,413,774.31, down from CNY 588,776,932.00 in the previous year, reflecting a decrease of 78.4%[107]. Governance and Compliance - The company received a disciplinary notice from the Shanghai Stock Exchange on May 18, 2022, involving the actual controller and financial director[68]. - There were no significant lawsuits or arbitration matters reported during the period[68]. - The financial statements were approved by the board of directors on August 15, 2022, ensuring compliance with regulatory requirements[124]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for the next 12 months[127].